Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Organon |
---|---|
Information provided by: | Organon |
ClinicalTrials.gov Identifier: | NCT00702195 |
The objective of this trial was to evaluate whether Org 36286 treatment in any Phase IIa clinical development trial of Org 36286 for OI or COH in assisted reproductive treatment programs was safe for pregnant subjects and their offspring. Data from subjects who participated in Trials 38805 and 38807 and became pregnant were evaluated.
Condition | Intervention |
---|---|
Pregnancy |
Drug: Org 36286 (corifollitropin alfa) Drug: Placebo Drug: recFSH |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials for the Development of Org 36286 (Corifollitropin Alfa). |
Enrollment: | 29 |
Study Start Date: | January 2002 |
Study Completion Date: | September 2003 |
Primary Completion Date: | September 2003 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Experimental Group 1
all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
|
Drug: Org 36286 (corifollitropin alfa)
single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
|
Experimental Group 2
Placebo
|
Drug: Placebo
single dose of placebo (administered under protocol 38805)
|
Experimental Group 3
all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
|
Drug: Org 36286 (corifollitropin alfa)
single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
|
Experimental Group 4
150 IU Puregon®
|
Drug: recFSH
150 IU recFSH daily (reference group administered under protocol 38807)
|
This was an open prospective follow-up trial to monitor pregnancy, delivery, and neonatal outcome of women who became pregnant during any Phase IIa clinical trial of Org 36286 for OI or COH for IVF. For this trial, no study specific assessments were required, but information obtained in standard practice was used.
Ages Eligible for Study: | 18 Years to 39 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
All women who became pregnant during Trials 38805 or 38807 were enrolled in Trial 38817
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | NV Organon, part of Schering-Plough Corporation ( Study Director ) |
Study ID Numbers: | 38817 |
Study First Received: | June 18, 2008 |
Last Updated: | June 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00702195 |
Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Neonatal outcome Congenital malformations In-Vitro Fertilization Controlled ovarian stimulation |
Follow-up Ovulation Induction Neonates |
Congenital Abnormalities Follicle Stimulating Hormone |